Among 98 women with axSpA, there were 335 pregnancies & 279 live births - 52% uncomplicated and 48% complicated (13%) multiple complications. axSpA had more Preterm birth (13 vs 5%), pre-eclampsia (7 vs 3%), Low birth Wt (8 vs 3%) https://t.co/i43HKduAgu https://t.co/XHbtH9YMrt

Baricitinib has been studied in 15 relapsing GCA pts - prospective, open-label, BARI 4 mg/d w/ GC taper. 14/15 completed 52 wks; 13/15 went into remission and d/c steroids. There was 1 Bari D/C for adverse event & 1 pt w/ serious AE. 1 pt relapsed. https://t.co/J5bjdPAFdm https://t.co/LsuSVP8L0R

Psoriasis RCT studied ADA+MTX (31) vs ADA (30); after 12 mos, a (non-significant) better drug survival w/ ADA-MTX (74 vs 59%; p=0.15). Also favoring, but not signif was PASI 75 (58 vs 37%). Fewer anti-ADA Abs seen w/ ADA-MTX (23 vs 60%; p<0.01) https://t.co/9CAQrpl6hU https://t.co/mr0ZaJ9mbW

Frailty: a decline in the physiologic reserve & function of several systems, leading to increased vulnerability and adverse health outcomes. Not just age; increased in RA (33%) more than AS or PsA. Frailty is dynamic & potentially reversible https://t.co/82hkGKoRxV https://t.co/7d9sycC6S2

Infants and children do get COVID; all races, 35% w/ comorbidities. CDC study from 99 counties in 14 US states shows betw 3/20 & 2/22 there were 2,637 hospitalized infants & children 0–4 yrs old; 24% went to ICU; there were 18 deaths https://t.co/mWyXAj2GbT https://t.co/MYN37JKziD

Abbvie announced that the FDA has approved Rinvoq (upadacitinib) for use in adults with active ulcerative colitis (after failing TNFi); approval based on 3 endoscopic UC trials. Starting dose is 45 mg/d, then maintain w/ 15 mg (some can get 30 mg) https://t.co/ZUbnkR7LMY https://t.co/dE1JkxzkSz

Individualized Therapy in Ankylosing Spondylitis Whether patients with AS would improve substantially with TNF inhibitor therapy was predicted with moderate to high accuracy based on a lab test and two measures of disease activity, researchers reported. https://t.co/hbbYqTiWGE https://t.co/Hx2U4y2e0F

Intravenous (IV) form of tramadol (Schedule IV) went in front of the FDA Drug Safety & Risk and Anesthetic/Analgesic Advisory Committees yesterday. They voted 14-8 against approval of IV tramadol (now available as tabs, liquid) https://t.co/AP2G7w8z1h https://t.co/lr9aLJSKi6

Low Dose IL-2 Efficacy in Rheumatoid Arthritis A novel biologic intervention trial has shown that subcutaneous, intermittent therapy with low-dose interleukin-2 (Ld-IL2) is potentially effective and safe in rheumatoid arthritis (RA). https://t.co/ycDgLT9EAA https://t.co/NJi48FZzAa

Metanalysis looked at the risk of psoriasis or PsA flare associated with steroid use. 11 retro- and prospective cohorts (4,170 820 pts) w/ 38% of PsA & 35% psoriasis Rx w/ systemic steroids. 10/11 studies did not show increased flares w/ steroids https://t.co/8o8hINFOrr https://t.co/85OYtWnGMJ

New download available on Methotrexate overview. https://t.co/dpyS4TS6tf https://t.co/2VsiqdX7WU